Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion

Reuters12-15 22:38

Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion

Fosun Pharma Industrial has entered into an agreement to acquire 8.6667% equity interest in a target company from Shiyin Investment and Shibirun for a total consideration of RMB143 million. Following the transaction, Fosun Pharma Industrial will also subscribe for newly increased registered capital in the target company, investing RMB1,269 million to secure a 46.3504% equity stake after completion. In addition, Fosun Pharma Industrial and the founder of the target company or their affiliates will jointly establish a special purpose vehicle (SPV), with Fosun Pharma Industrial holding a 51% stake and the founder or affiliates holding 49%. The SPV will acquire a 2% equity interest in the target company from Shanghai Yaoqijiu for RMB1 or the minimum legally permissible price. The transaction aims to strengthen Fosun Pharma Group's position in the market and advance clinical development for Alzheimer's disease treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251215-11956263), on December 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591422006?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591422006","market":"fut","top_or_hot":-1,"title":"Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fosun Pharma Industrial has entered into an agreement to acquire 8.6667% equity interest in a target company from Shiyin Investment and Shibirun for a total consideration of RMB143 million. Following the transaction, Fosun Pharma Industrial will also subscribe for newly increased registered capital in the target company, investing RMB1,269 million to secure a 46.3504% equity stake after completion. In addition, Fosun Pharma Industrial and the founder of the target company or their affiliates will jointly establish a special purpose vehicle (SPV), with Fosun Pharma Industrial holding a 51% stake and the founder or affiliates holding 49%. The SPV will acquire a 2% equity interest in the target company from Shanghai Yaoqijiu for RMB1 or the minimum legally permissible price. The transaction aims to strengthen Fosun Pharma Group's position in the market and advance clinical development for Alzheimer's disease treatments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251215-11956263), on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-15 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fosun Pharma Industrial has entered into an agreement to acquire 8.6667% equity interest in a target company from Shiyin Investment and Shibirun for a total consideration of RMB143 million. Following the transaction, Fosun Pharma Industrial will also subscribe for newly increased registered capital in the target company, investing RMB1,269 million to secure a 46.3504% equity stake after completion. In addition, Fosun Pharma Industrial and the founder of the target company or their affiliates will jointly establish a special purpose vehicle (SPV), with Fosun Pharma Industrial holding a 51% stake and the founder or affiliates holding 49%. The SPV will acquire a 2% equity interest in the target company from Shanghai Yaoqijiu for RMB1 or the minimum legally permissible price. The transaction aims to strengthen Fosun Pharma Group's position in the market and advance clinical development for Alzheimer's disease treatments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251215-11956263), on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL736gGY:1","article_id":"2591422006","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591422006","pubTimestamp":1765809515,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fosun Pharma Industrial has entered into an agreement to acquire 8.6667% equity interest in a target company from Shiyin Investment and Shibirun for a total consideration of RMB143 million. Following the transaction, Fosun Pharma Industrial will also subscribe for newly increased registered capital in the target company, investing RMB1,269 million to secure a 46.3504% equity stake after completion. In addition, Fosun Pharma Industrial and the founder of the target company or their affiliates will jointly establish a special purpose vehicle , with Fosun Pharma Industrial holding a 51% stake and the founder or affiliates holding 49%. The SPV will acquire a 2% equity interest in the target company from Shanghai Yaoqijiu for RMB1 or the minimum legally permissible price. The transaction aims to strengthen Fosun Pharma Group's position in the market and advance clinical development for Alzheimer's disease treatments.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0175":"白马股","BK0028":"国家队","BK0012":"证金概念","00656":"复星国际","BK0183":"MSCI概念","BK1230":"工业集团企业","BK0060":"抗癌","BK0096":"民营医院","BK0196":"行业龙头","BK0188":"融资融券","BK0239":"医药制造","BK0187":"一线龙头"},"translate_title":"复星医药将以12.7亿元收购阿尔茨海默病药物开发商多数股权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"00656":0.9},"content_text":"Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion\n    \n\n        Fosun Pharma Industrial has entered into an agreement to acquire 8.6667% equity interest in a target company from Shiyin Investment and Shibirun for a total consideration of RMB143 million. Following the transaction, Fosun Pharma Industrial will also subscribe for newly increased registered capital in the target company, investing RMB1,269 million to secure a 46.3504% equity stake after completion. In addition, Fosun Pharma Industrial and the founder of the target company or their affiliates will jointly establish a special purpose vehicle (SPV), with Fosun Pharma Industrial holding a 51% stake and the founder or affiliates holding 49%. The SPV will acquire a 2% equity interest in the target company from Shanghai Yaoqijiu for RMB1 or the minimum legally permissible price. The transaction aims to strengthen Fosun Pharma Group's position in the market and advance clinical development for Alzheimer's disease treatments.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251215-11956263), on December 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591422006","isCrawlerRequest":true}